Rituximab gets US approval for common leukaemia
19 February 2010
Malini Guha
The US
FDA has approved
Roche/
Biogen Idec's anti-CD20 drug Rituxan/MabThera (rituximab) plus chemotherapy for people with either previously untreated or previously treated (relapsed or refractory) chronic lymphocytic leukaemia (CLL).
Last year, MabThera was approved in the EU for these same...
Please Login to read the full article.
19 February 2010
Malini Guha
Last year, MabThera was approved in the EU for these same...
Please Login to read the full article.
RELATED CONTENT
NEWS
- New data strengthen profile for Pharmacyclics' novel blood cancer drug
- Positive Phase II lymphoma data for Genmab/GSK's ofatumumab
- Positive Phase II data for Teva/CureTech's DLBCL antibody treatment
- Mundipharma pays Allos $50 million up front for ex-US rights to lymphoma drug
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
